Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study

Stauch, S; Kircheis, G.; Adler, Guideo; Beckh, K; Ditschuneit, H.; Görtelmeyer, Roman; Hendricks, R; Heuser, A.; Karoff, C; Malfertheiner, Peter; Mayer, Dirk; Rösch, Wolfgang; Steffens, Jakob

doi:10.1016/s0168-8278(98)80237-7

Cited by 152 publications

(109 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…L-ornithine-L-aspartate is a complex amino acid that stimulates both the urea cycle and muscle protein synthesis. In two randomized, double-blind studies for the treatment of HE type C, L-ornithine-L-aspartate was superior to placebo in improving mental status, decreasing hyperammonemia, and improving psychometric test scores when administered orally [45] or intravenously [46]. A recent meta-analysis demonstrated the value of L-ornithine-L-aspartate in the treatment of patients with mild HE (grade I --II); no improvement was observed in patients with severe encephalopathy (grades III --IV) or in patients with minimal HE [47].…”

Section: Nutritional Statusmentioning

confidence: 96%

Pharmacotherapy of hepatic encephalopathy in cirrhosis

Romero‐Gómez

2010

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Section: Nutritional Statusmentioning

confidence: 96%

Pharmacotherapy of hepatic encephalopathy in cirrhosis

Romero‐Gómez

2010

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

“…Stauch et al 24 showed improvement in the number connection test and blood ammonia level with the use of LOLA as compared with placebo in overt HE. The data for LOLA are still conflicting.…”

Section: L-ornithine-l-aspartatementioning

confidence: 99%

Managing encephalopathy in the outpatient setting

Rathi

Dhiman

2016

Clinical Liver Disease

View full text Add to dashboard Cite

In cirrhosis of liver, hepatic encephalopathy (HE) has an important impact on health-related quality of life. It is important to define whether HE is episodic, recurrent, or persistent; types A, B, or C; overt HE or covert HE; and spontaneous or precipitated. The overt HE is clinically evident and needs hospitalization. Nonabsorbable disaccharides, rifaximin, and probiotics are proven to be useful in the treatment of overt HE. Covert HE includes both minimal HE and grade I HE. It is not apparent on routine clinical examination. Presence of poor work productivity, increased accidental injuries on complex machinery and driving, etc., raise the suspicion of cognitive dysfunction. Specialized neurocognitive testing like psychometric HE, computerized tests like critical flicker frequency tests, inhibitory control tests, Stroop encephalopathy tests, and electroencephalography are needed to diagnose overt HE. Various studies have shown lactulose and rifaximin to be useful in overt HE. However, presence of persistent and recurrent HE in cirrhosis is an indication for liver transplant. Lactulose is effective both in improving reversal of minimal HE and in reducing the risk of development of overt HE.

show abstract

“…Наши собственные результаты лечения ПЭ с примене-нием Орнилатекса сопоставимы с общемировым опытом: эффективность L-орнитина-L-аспартата (Орнилатекс) доказана в широкомасштабных клинических исследова-ниях с качественным дизайном, что следует из анализа литературных данных как русскоязычных, так и англо-язычных ресурсов [30].…”

Section: снижение памяти 71%unclassified